Liquid biopsiEs fOr luNg AllogRaft Damage classificatiOn - LEONARDO
LEONARDO
Liquid Biopsies for Lung Allograft Damage Classification
1 other identifier
observational
146
1 country
1
Brief Summary
LTx has the shortest survival of all solid organ transplants. The complex and time-demanding diagnostics of allograft dysfunction are a significant reason for this. The current study aims overarchingly to improve survival after lung transplantation (LTx) through precise and fast diagnostics. The specific aim is to develop direct-to-clinical implementation biomarkers for the most important aspects of long-term survival after LTx. An in-house-developed PCR-based cell-free-DNA methodology (cf-DNA) will be used for allograft damage and combined with specific other biomarkers to identify damage type. The current clinical golden standard for damage identification will be performed at every sampling instance. The research will be a single-centre prospective observational cohort study. The control samples at all time points will consist of the samples without allograft damage. Blood will be drawn at fixed time points and clinical events. All analyses will be performed at a separate lab, blinded to the patient's status. .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 28, 2024
CompletedFirst Posted
Study publicly available on registry
November 7, 2024
CompletedStudy Start
First participant enrolled
November 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
September 16, 2025
September 1, 2025
5 years
October 28, 2024
September 15, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Damage distinction
Null hypothesis: Levels of Cf-DNA is not different at samples taken with allograft damage and no allograft damage.
One month, three months, one year, three years, five years
Secondary Outcomes (1)
Damage detection Limit
One month, three months, one year, three years, five years
Study Arms (1)
Lung transplanted patients
All eligible patients were transplanted and followed up within the catchment area of the participating centre.
Interventions
Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients
Eligibility Criteria
Newly lung transplanted patients within scandinavia
You may qualify if:
- Luing Transplanted and followed up within the reach of the study paricipating centres.
- A good understanding to read and write within the languages in which the consent is provided.
You may not qualify if:
- Not Lung Transplanted or not followed up within the reach of the study paricipating centres.
- No good understanding to read and write within the languages in which the consent is provided.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jesper Magnussonlead
Study Sites (1)
Sahlgrenska University hospital
Gothenburg, Västra Götaland County, 413 45, Sweden
Biospecimen
Cell free DNA
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD, PhD, Associate professor
Study Record Dates
First Submitted
October 28, 2024
First Posted
November 7, 2024
Study Start
November 15, 2024
Primary Completion (Estimated)
December 1, 2029
Study Completion (Estimated)
December 1, 2030
Last Updated
September 16, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share